[Effectiveness and safety of a hypotensive preservative-free drug in long-term therapy of glaucoma].

Taflotan effectively decreases IOP in newly diagnosed glaucoma patients, maintains stable automated perimetry indices and RNFL thickness, and does not affect the ocular surface throughout 12 months of therapy.